伴糖代谢异常冠心病患者冠脉病变的临床分析
|
摘要
目的：分析伴糖代谢异常、血糖水平不同的冠心病患者的冠状动脉病变特征。
方法：随机选择130例行经皮冠状动脉造影术确诊为冠心病的患者，均来自吉林市中心医院心内二科。根据血糖水平，分成单纯空腹血糖调节受损冠心病组(1组)，混合型糖耐量减低冠心病组(2组)，并糖尿病冠心病组(3组)，血糖正常冠心病组(4组，对照组)。分别对四组病人年龄，性别，血糖(空腹血糖及餐后2小时血糖)水平，血脂及冠状动脉病变支数进行分析比较。
结果：四组病变情况不相互独立：3组与4组，3组与1组比较，3组多支病变率明显高于1组、4组，且显著性差异(P＜0.05)；2组与3组、1组与4组比较则无显著性差异(P＞0.05)。3组多支病变发病率(86.84％)明显高于4组(66％)与1组(57.89％)，3组多支发病率(86.84％)与2组(82.61％)无显著性差异(P＞0.05)，1组多支发生率(57.89％)与4组(66％)无显著性差异(P＞0.05)。
结论：混合型糖耐量异常伴冠心病患者与伴糖尿病冠心病患者的冠状动脉病变情况相似，多支病变率高于单纯空腹血糖调节受损冠心病组与血糖正常冠心病组，餐后血糖与冠心病多支病变的相关性更高于单纯空腹血糖调节受损。
Objective: To analyze the features of the coronary artery lesion in patients withcoronary heart disease complicated with glyconetabolic disorder.
Methods: All the patients with coronary heart disease(CHD) is from the CenteryHospital of JiLin city the second department Cardiology, total 130.They were dividedfour groups by the different glucose: the first is isolated impaired fastingglucose(Ⅰ-IFG),the second is combinedⅠ-IFG and isolated impaired glucosetolerance(IFG/IGT),the thirst is diabetes mellitus(DM),the fouth is simple CHD group.TO analyze the age, gender, blood glucose (fasting glucose and 2-hours glucose),and the number of coronary disease lesion, so as to analyze the statistic.
Results and Conclusion:: The incidence rate of multi-vessel coronary lesion inthe third group(86.84%) is obviously higher than the forth(66%) and first(57.89%)group, P＜0.05. There was no significant difference in the incidence rate ofmulti-vessel coronary lesion between the third (86.84%)and second (82.61%)group,between the first(57.89%) and forth(66%).
方法：随机选择130例行经皮冠状动脉造影术确诊为冠心病的患者，均来自吉林市中心医院心内二科。根据血糖水平，分成单纯空腹血糖调节受损冠心病组(1组)，混合型糖耐量减低冠心病组(2组)，并糖尿病冠心病组(3组)，血糖正常冠心病组(4组，对照组)。分别对四组病人年龄，性别，血糖(空腹血糖及餐后2小时血糖)水平，血脂及冠状动脉病变支数进行分析比较。
结果：四组病变情况不相互独立：3组与4组，3组与1组比较，3组多支病变率明显高于1组、4组，且显著性差异(P＜0.05)；2组与3组、1组与4组比较则无显著性差异(P＞0.05)。3组多支病变发病率(86.84％)明显高于4组(66％)与1组(57.89％)，3组多支发病率(86.84％)与2组(82.61％)无显著性差异(P＞0.05)，1组多支发生率(57.89％)与4组(66％)无显著性差异(P＞0.05)。
结论：混合型糖耐量异常伴冠心病患者与伴糖尿病冠心病患者的冠状动脉病变情况相似，多支病变率高于单纯空腹血糖调节受损冠心病组与血糖正常冠心病组，餐后血糖与冠心病多支病变的相关性更高于单纯空腹血糖调节受损。
Objective: To analyze the features of the coronary artery lesion in patients withcoronary heart disease complicated with glyconetabolic disorder.
Methods: All the patients with coronary heart disease(CHD) is from the CenteryHospital of JiLin city the second department Cardiology, total 130.They were dividedfour groups by the different glucose: the first is isolated impaired fastingglucose(Ⅰ-IFG),the second is combinedⅠ-IFG and isolated impaired glucosetolerance(IFG/IGT),the thirst is diabetes mellitus(DM),the fouth is simple CHD group.TO analyze the age, gender, blood glucose (fasting glucose and 2-hours glucose),and the number of coronary disease lesion, so as to analyze the statistic.
Results and Conclusion:: The incidence rate of multi-vessel coronary lesion inthe third group(86.84%) is obviously higher than the forth(66%) and first(57.89%)group, P＜0.05. There was no significant difference in the incidence rate ofmulti-vessel coronary lesion between the third (86.84%)and second (82.61%)group,between the first(57.89%) and forth(66%).
引文
[1]．向红丁．1996年全国糖尿病流行病学特点基线调查报告[J]．中国糖尿病杂志，1998，6(1)：3．
[2]．孙纪新，翟新灵，符云峰．糖尿病并发心血管疾病的机理研究进展[J]．心血管病学进展，2004，25(4)：299-302．
[3]．潘长玉．有关国际糖尿病联盟专题研讨IGT／IFG的情况[J]．国外医学·内分泌分册，2003，23(3)：151-152．
[4]. Vaccaro O, Stamler J, Ndator JO. Sisteen-year coronary in black and white men with diabefeo screened for the multiple risk factor in favertion frid(MRFIT). Int J Epidemio I, 1998, 27: 636.
[5]．姚君厘．糖尿病和大血管病变[J]．上海医药，2006，27(6)：253-256．
[6]．陈在嘉，高润霖．冠心病，北京：人民卫生出版社，第一版．2002：503．
[7]．许瑞敏，李玉光，阎纯英，等．2型糖尿病冠状动脉病变与血脂关系的临床研究[J]．中国现代医学杂志，2003，13(10)：80-85．
[8]. Le Feuvre C, Borentain M, Beygui F, et al. Comparison of short-term and long-term outcomes of coronary angioplasty in patients with and without diabetes mellitus and with and without hemodialysis. [J]. Am J Cardiol, 2003, 92(6): 721-725.
[9]. Menotti A ,Puddu PE; Lanti M. Comparison of the Framingham risk functionbased coronary chart with risk function from an Italian population study. Eur Heart J 2000: 21(5): 365-370.
[10]．蒋国彦主编．实用糖尿病学，北京：人民卫生出版社，第二版．1992：268．
[11]．何雪珍．糖耐量减低与冠心病发病率的临床研究．中国临床医药研究杂志，2006，154：10-11．
[12]．徐成斌．防治糖尿病粥样硬化性心血管的新观点[J]．国外医学-内分泌分册，2003，23(3)：172-174．
[13]．常静．中国心脏调查结果证实多数冠心病患者有未诊断的血糖异常[J]．中 华医学信息导报，2006，21(12)：10．
[14]．楚新梅，孟竹，戴文英，等．新疆地区维、汉民族冠状动脉粥样硬化性心脏病患者血脂分析[J]．中国临床康复，2003，7(9)：1408-1409．
[15]. Song SH, Brown PM. Coronary heard disease risk assessment in diabetes mellitus:comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med. 2004,21(3):238-245.
[16]．徐懿，李月华．糖尿病合并冠状动脉粥样硬化性心脏病的发病及其相关特征[J]．中国临床康复：2006，10(20)：130-132．
[17]. Gerseein HC. Glulose: A Coutinuous risk factor for cardiovasucular disease. DiabeeM ell, 1997, 14(3): 25.
[18]. Hingorani AD, Liang CF, Fatibene J, et al. A common variant of the endotheliaI nitric oxide synthase is a major risk factor for coronary artery disease in the UK. Circulation, 1999, 100 (14): 1 515.
[19]. Goodwin TM, Gherman RB, Hameed A, et al. Favorable response of Eisenmenger syndrome tO inhaled nitric oxide during pregnancy. Am J Obstet Gynecol, 1999, 189(1): 64.
[20]. Kaplan NM. The deadly quartet: uppey-body obesity, glucose intolerance, hyperttigly ceridemia and hypertension. Arch Intern M ed, 1998, 149: 154.
[21]. Ouchi N, Kihara S, Arita Y, et al Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103 (8): 10 57-63.
[22]. Furuhashi M, Ura N, Moniwa N, Shinshi Y, Kouzu H, Nishihara M, et al. Possible impairment of transcardiac utilization of adiponectin in patients with type2 diabetes [J]. Diabetes Care, 2004, 27 (9): 2217-2221.
[23]. Falcone C, Nespoli L, Geroldi D, et al. Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease[J].Int J Cardiol, 2003, 90(2-3): 219-227.
[24]．郭静文．糖尿病并发冠心病的研究进展[J]．中国全科医学，2003，6：523．
[25]．李延彬，刘淑艳，李莉．心肌梗死伴糖代谢异常精辟冠脉成形术的临床特点及相关危险因素分析[J]．医师进修杂志，2003，26(11)：35-39．
[26]. Diabetes. 2006, 55(7): 2148.
[27]．潘孝仁，李光伟，胡英华，等．饮食和运动干预对糖尿病发病率的英雄-530例糖耐量减低人群6年前瞻性观察[J]．中华内科杂志，1995，34：108-112．
[28]．潘长玉．中国面临糖尿病的挑战[J]．国外医学-内分泌分册，2002，22(6)：356．
[29]. The DECODE study group. Glucose tolerance and mortality comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999,354:617-621.
[30]．李赟，刘江华．波动性高血糖与糖尿病大血管并发症[J]．国外医学内分泌学分册，2004，24(6)：400-401．
[31]. Hanefeld M,Fischer S, Julius U, et al. The DIS group risk factors for myocardial infarction and death in newly detected NIDDM-. the Diabetes Intervention Study, 11-years follow-up. Diabetologia, 1996,39:1577-1583.
[32]．郝民安．降低餐后血糖十分重要[J]．医药与保健-糖尿病之友，2006，14(12)：42．
[33] 高妍．餐后高血糖与心血管合并症[J]．国外医学内分泌学分册，2002，22(3)：145-148．
[1]．胡大一，黄元铸．急性冠状动脉综合征．第一版．北京：人民卫生出版社，2001，26-36．
[2]．叶任高，陆再英，等．内科学．第六版，北京：人民出版社，2004，263-272．
[3]. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches[J]. VaseMed, 1998, 3(3): 2311-2329.
[4]．许俊堂，胡大一．动脉粥样硬化血栓形成[J]．中国医刊，2006，41(7)：4-5．
[5]．赵水平，王钟林，陆宗良．临床血脂学．长沙：湖南科学技术出版社．1997，71-72．
[6]．汪俊军，顾振华，张春妮，等．脂蛋白(a)氧化和自身免疫与动脉粥样硬化的关系[J]．医学研究生学报，2005，18(8)：740—742．
[7]．胡大一，向小平．动脉粥样硬化早期检测的临床应用——大动脉僵硬度(弹性)和功能检查，中国心血管病研究杂志 2007，5(2)：81-82．
[8]. Hansson GK. Inflammation. atherosclerosis and coronary artery disease[J]. Ⅳ Engl., Med, 2005, 352(16): 1685-1695.
[9]. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences[J]. Ann Intern Med, 2001, 134(3): 224-238.
[10]．周志斌，郭毅．不稳定性动脉粥样硬化斑块的特点及主要形成机制[J]．国外医学脑血管疾病分册，2004，12(2)：137-140．
[11]．钱菊英，葛均波，等，急性冠状动脉综合征和稳定型心绞痛患者的血管内超声显像结果[J]．中国介入心脏病学杂志2005，13(2)：71-75．
[12]. Hsueh WC, Cole SA, Shuldiner AR, et al. Interactions between variants in the beta. 3-adrenergic receptor and peroxisome proliferator-aetiwted receptor-gamma2 genes and obesity[J]. Diabetes Care, 2001, 24(4): 672-677.
[13]. Munger MA, Hawkins DW Atherothrombosis: epidemiology, pathophysiology, and prevention [J]. J Am Pharm Assoc(Wash DC), 2004, 44(2 Suppl 1): s5—12: quiz S12-3.
[14]. Viles—Gonzalez JF, Anand SX, Valdiviezo C, et. al. Update in atherothrombotic disease[J]. Mt Sinai, Med, 2004, 71(3): 197-208.
[15]. Callow AD. Endothelial dysfunction in atherosclemsis[J]. Vascul Pharmacot, 2002, 38(5): 257-258.
[16]．汪建高，王海燕．卡托普利对日本大耳白兔动脉粥样硬化影响的研究[J]．中国心血管杂志，2003，8(6)：381-382．
[17]. Lerman A, Holmes DR Jr, Bell MR, et al. Endothelin in coronaryendothelial dysfunction and early atherosclerosis in humans[J]. Circulation, 1995, 92(9): 2426—2431.
[18]. Golino P, Piscione F, Willemon JT, et al. Divergent effects of semtonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients[J].Ⅳ Engl., Med, 1991, 324(10): 641-648.
[19]．姚春海，崔长琼，张继才，等．冠心病患者病变程度与血清氧化修饰的低密度脂蛋白C反应蛋白的关系[J]．临床心血管病杂志，2002，18(11)：559-561．
[20]．杜菊兰，万汝根．胆红素含量与冠心病的关系[J]．中华检验医学杂志，2003，26(10)：624—625．
[21]．马建慧，张梅，等，氧化型低密度脂蛋白与动脉粥样硬化[J]．农垦医学，2003，25(2)：131-133．
[22]．唐植辉，汪南平，等．血流剪切力在动脉粥样硬化形成中的作用[J]．生理科学进展，2007，38(1)：37-42．
[23]. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis [J]. Biochem Soc Trans, 2003, 31(5): 1059—1061.
[24]. Geisler. T, Bhatt DL. The role of inflammation inatherothrombusis: current and future strategies of medical treatment[J]. Med SciMonit, 2004, 10(12): RA308-316.
[25]．龙汉安，肖秀丽，马跃荣．动脉粥样硬化研究进展—炎症与感染在动脉粥样硬化形成中的作用[J]．中国心血管病研究杂志，2003，1(2)：152-153
[26]. Cha JK, Jo WS, Shin HC, et al. Increased platelet CD63 andP-selectin expression persist in atherosclerotic ischemic stroke[J].Platelets, 2004,15(1):3-7.
[27]．陈字杰，陆信武，蒋米尔．P-选择素与动脉粥样硬化形成[J]．国外医学·生理、病理科学与临床分册，2002，22(4)：323-325．
[28]．许丹焰．P选择素在心血管疾病中的研究进展[J]．国外医学生理病理分册，1997，17：252-254．
[29]．倪俊．选择素拮抗治疗[J]．国外医学生理病理分册，1998，18：306-308．
[30]. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated Creactive protein levels and impared endothelial vasoreaetivity in patients with coronary artery disease. Circulation, 2000, 102:1000—1006.
[31]. Ridker PM. Stampfer MJ. Rifai N, Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease[J]. JAMA, 2001, 285(19): 2481-2485.
[32]. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000, 342(12): 836-844.
[33]．陈凤英，高炜，唐朝枢．CD40—CD40配体与动脉粥样硬化的研究进展[J]．中国动脉硬化杂志，2006年，14(8)：731-733．
[34]．谢扬，饶邦复．动脉粥样硬化血栓形成[J]．世界今日医学杂志，2005；6(4)：236-240．
[35]. Herman MP, Sukhova GK, Libby P, et al. Expression of neutmphil- collagenase(matrix metalloproteinase-8) in. human atheroma: a novelcollagenolytic pathway suggested by transcriptional profiling[J]. Circulation, 2001, 104(16).: 1899-1904.
[36]. Libby P, Geng YJ, Aikawa M, et al. Macrophages and athemsclerotic plaque stability[J]. Curt Opin Lipidol, 1996, 7(5): 330-335.
[37]. Badimon JJ, Lettino M, roschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombo—genicity under flow conditions[J]. Circulation, 1999, 99(14): 1780—1787.
[38]. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atheroselerotic plaques[J]. Circulation, 1997, 95(3): 594-599.
[39]. Moons AH, Levi M, Peters IL1. Tissue factor and coronary artery disease[J]. Cardiovasc Res, 2002, 53(2): 313-325.
[40]. Tedgui A. Mallat Z. Apoptosis as a determinant of atherothrombosis[J], Thromb Haemost, 2001, 86(1): 420-426.
[41]. Chamorro A. Role of inflammation in stroke and atherothrombosis[J]. Cerebrovasc Dis, 2004, 17(Suppl 3): 1-5.
[42]．周卫东．氧化型低密度脂蛋白的血管运动效应[J]．国外医学生理病理科学与临床分册，2000，20(1)：52-54．
[43]．赵洪东，周天虹．动脉粥样硬化与细胞凋亡[J]．武警医学院学报，2001，10(2)：171-173．
[44]. Hutter R, Valdiviezo C, Bernhard V, et al. Caspase—3 and Tissue Factor Expression in Lipid—Rich Plaque Macro phages. Evidence for Apoptosis as Link Between Inflammation and Atherothrombosis[J].Circulation, 2004, 109(16): 2001-2008.
[45]. Mallat Z. Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease[J]. Circ.Res, 2001, 88(10): 998-1003.
[46]. Mallat Z, Benamer H, Hugel B, et al.. Elevated levels of shed membrane micropartieles with pracoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes[J], circulation, 2000, 101(8): 841—843.
[47]．黄成磊，罗心平．阻断细胞凋亡药物在冠心病治疗中的研究[J]．国际心血管病杂志，2006，33(6)：377-380．
[48]．刘彤，沈潞华．雌激素抑制去卵巢家兔实验性主动脉硬化的形成[J]．中国动脉硬化杂志，1998，6(4)：121—123．
[49]．吴练秋，赵庆伟．糖皮质激素与动脉粥样硬化的关系[J]．中国动脉硬化杂志，1999，7(4)：360-362．
[50]．陈浩，严晓伟．过氧化物增殖激活受体在动脉粥样硬化形成过程中的作用[J]．世界医学杂志，2004，8(1)：70-72．
[51]．胡琴，张运．过氧化体增殖物激活型受体各亚型与动脉粥样硬化形成[J]．中国动脉硬化杂志，2005，13(5)：662-666．
[52]. Raueh U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical eonsequencesv[J]. Ann Intern Med, 2001, 134(3): 224—23.
[2]．孙纪新，翟新灵，符云峰．糖尿病并发心血管疾病的机理研究进展[J]．心血管病学进展，2004，25(4)：299-302．
[3]．潘长玉．有关国际糖尿病联盟专题研讨IGT／IFG的情况[J]．国外医学·内分泌分册，2003，23(3)：151-152．
[4]. Vaccaro O, Stamler J, Ndator JO. Sisteen-year coronary in black and white men with diabefeo screened for the multiple risk factor in favertion frid(MRFIT). Int J Epidemio I, 1998, 27: 636.
[5]．姚君厘．糖尿病和大血管病变[J]．上海医药，2006，27(6)：253-256．
[6]．陈在嘉，高润霖．冠心病，北京：人民卫生出版社，第一版．2002：503．
[7]．许瑞敏，李玉光，阎纯英，等．2型糖尿病冠状动脉病变与血脂关系的临床研究[J]．中国现代医学杂志，2003，13(10)：80-85．
[8]. Le Feuvre C, Borentain M, Beygui F, et al. Comparison of short-term and long-term outcomes of coronary angioplasty in patients with and without diabetes mellitus and with and without hemodialysis. [J]. Am J Cardiol, 2003, 92(6): 721-725.
[9]. Menotti A ,Puddu PE; Lanti M. Comparison of the Framingham risk functionbased coronary chart with risk function from an Italian population study. Eur Heart J 2000: 21(5): 365-370.
[10]．蒋国彦主编．实用糖尿病学，北京：人民卫生出版社，第二版．1992：268．
[11]．何雪珍．糖耐量减低与冠心病发病率的临床研究．中国临床医药研究杂志，2006，154：10-11．
[12]．徐成斌．防治糖尿病粥样硬化性心血管的新观点[J]．国外医学-内分泌分册，2003，23(3)：172-174．
[13]．常静．中国心脏调查结果证实多数冠心病患者有未诊断的血糖异常[J]．中 华医学信息导报，2006，21(12)：10．
[14]．楚新梅，孟竹，戴文英，等．新疆地区维、汉民族冠状动脉粥样硬化性心脏病患者血脂分析[J]．中国临床康复，2003，7(9)：1408-1409．
[15]. Song SH, Brown PM. Coronary heard disease risk assessment in diabetes mellitus:comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med. 2004,21(3):238-245.
[16]．徐懿，李月华．糖尿病合并冠状动脉粥样硬化性心脏病的发病及其相关特征[J]．中国临床康复：2006，10(20)：130-132．
[17]. Gerseein HC. Glulose: A Coutinuous risk factor for cardiovasucular disease. DiabeeM ell, 1997, 14(3): 25.
[18]. Hingorani AD, Liang CF, Fatibene J, et al. A common variant of the endotheliaI nitric oxide synthase is a major risk factor for coronary artery disease in the UK. Circulation, 1999, 100 (14): 1 515.
[19]. Goodwin TM, Gherman RB, Hameed A, et al. Favorable response of Eisenmenger syndrome tO inhaled nitric oxide during pregnancy. Am J Obstet Gynecol, 1999, 189(1): 64.
[20]. Kaplan NM. The deadly quartet: uppey-body obesity, glucose intolerance, hyperttigly ceridemia and hypertension. Arch Intern M ed, 1998, 149: 154.
[21]. Ouchi N, Kihara S, Arita Y, et al Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103 (8): 10 57-63.
[22]. Furuhashi M, Ura N, Moniwa N, Shinshi Y, Kouzu H, Nishihara M, et al. Possible impairment of transcardiac utilization of adiponectin in patients with type2 diabetes [J]. Diabetes Care, 2004, 27 (9): 2217-2221.
[23]. Falcone C, Nespoli L, Geroldi D, et al. Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease[J].Int J Cardiol, 2003, 90(2-3): 219-227.
[24]．郭静文．糖尿病并发冠心病的研究进展[J]．中国全科医学，2003，6：523．
[25]．李延彬，刘淑艳，李莉．心肌梗死伴糖代谢异常精辟冠脉成形术的临床特点及相关危险因素分析[J]．医师进修杂志，2003，26(11)：35-39．
[26]. Diabetes. 2006, 55(7): 2148.
[27]．潘孝仁，李光伟，胡英华，等．饮食和运动干预对糖尿病发病率的英雄-530例糖耐量减低人群6年前瞻性观察[J]．中华内科杂志，1995，34：108-112．
[28]．潘长玉．中国面临糖尿病的挑战[J]．国外医学-内分泌分册，2002，22(6)：356．
[29]. The DECODE study group. Glucose tolerance and mortality comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999,354:617-621.
[30]．李赟，刘江华．波动性高血糖与糖尿病大血管并发症[J]．国外医学内分泌学分册，2004，24(6)：400-401．
[31]. Hanefeld M,Fischer S, Julius U, et al. The DIS group risk factors for myocardial infarction and death in newly detected NIDDM-. the Diabetes Intervention Study, 11-years follow-up. Diabetologia, 1996,39:1577-1583.
[32]．郝民安．降低餐后血糖十分重要[J]．医药与保健-糖尿病之友，2006，14(12)：42．
[33] 高妍．餐后高血糖与心血管合并症[J]．国外医学内分泌学分册，2002，22(3)：145-148．
[1]．胡大一，黄元铸．急性冠状动脉综合征．第一版．北京：人民卫生出版社，2001，26-36．
[2]．叶任高，陆再英，等．内科学．第六版，北京：人民出版社，2004，263-272．
[3]. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches[J]. VaseMed, 1998, 3(3): 2311-2329.
[4]．许俊堂，胡大一．动脉粥样硬化血栓形成[J]．中国医刊，2006，41(7)：4-5．
[5]．赵水平，王钟林，陆宗良．临床血脂学．长沙：湖南科学技术出版社．1997，71-72．
[6]．汪俊军，顾振华，张春妮，等．脂蛋白(a)氧化和自身免疫与动脉粥样硬化的关系[J]．医学研究生学报，2005，18(8)：740—742．
[7]．胡大一，向小平．动脉粥样硬化早期检测的临床应用——大动脉僵硬度(弹性)和功能检查，中国心血管病研究杂志 2007，5(2)：81-82．
[8]. Hansson GK. Inflammation. atherosclerosis and coronary artery disease[J]. Ⅳ Engl., Med, 2005, 352(16): 1685-1695.
[9]. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences[J]. Ann Intern Med, 2001, 134(3): 224-238.
[10]．周志斌，郭毅．不稳定性动脉粥样硬化斑块的特点及主要形成机制[J]．国外医学脑血管疾病分册，2004，12(2)：137-140．
[11]．钱菊英，葛均波，等，急性冠状动脉综合征和稳定型心绞痛患者的血管内超声显像结果[J]．中国介入心脏病学杂志2005，13(2)：71-75．
[12]. Hsueh WC, Cole SA, Shuldiner AR, et al. Interactions between variants in the beta. 3-adrenergic receptor and peroxisome proliferator-aetiwted receptor-gamma2 genes and obesity[J]. Diabetes Care, 2001, 24(4): 672-677.
[13]. Munger MA, Hawkins DW Atherothrombosis: epidemiology, pathophysiology, and prevention [J]. J Am Pharm Assoc(Wash DC), 2004, 44(2 Suppl 1): s5—12: quiz S12-3.
[14]. Viles—Gonzalez JF, Anand SX, Valdiviezo C, et. al. Update in atherothrombotic disease[J]. Mt Sinai, Med, 2004, 71(3): 197-208.
[15]. Callow AD. Endothelial dysfunction in atherosclemsis[J]. Vascul Pharmacot, 2002, 38(5): 257-258.
[16]．汪建高，王海燕．卡托普利对日本大耳白兔动脉粥样硬化影响的研究[J]．中国心血管杂志，2003，8(6)：381-382．
[17]. Lerman A, Holmes DR Jr, Bell MR, et al. Endothelin in coronaryendothelial dysfunction and early atherosclerosis in humans[J]. Circulation, 1995, 92(9): 2426—2431.
[18]. Golino P, Piscione F, Willemon JT, et al. Divergent effects of semtonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients[J].Ⅳ Engl., Med, 1991, 324(10): 641-648.
[19]．姚春海，崔长琼，张继才，等．冠心病患者病变程度与血清氧化修饰的低密度脂蛋白C反应蛋白的关系[J]．临床心血管病杂志，2002，18(11)：559-561．
[20]．杜菊兰，万汝根．胆红素含量与冠心病的关系[J]．中华检验医学杂志，2003，26(10)：624—625．
[21]．马建慧，张梅，等，氧化型低密度脂蛋白与动脉粥样硬化[J]．农垦医学，2003，25(2)：131-133．
[22]．唐植辉，汪南平，等．血流剪切力在动脉粥样硬化形成中的作用[J]．生理科学进展，2007，38(1)：37-42．
[23]. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis [J]. Biochem Soc Trans, 2003, 31(5): 1059—1061.
[24]. Geisler. T, Bhatt DL. The role of inflammation inatherothrombusis: current and future strategies of medical treatment[J]. Med SciMonit, 2004, 10(12): RA308-316.
[25]．龙汉安，肖秀丽，马跃荣．动脉粥样硬化研究进展—炎症与感染在动脉粥样硬化形成中的作用[J]．中国心血管病研究杂志，2003，1(2)：152-153
[26]. Cha JK, Jo WS, Shin HC, et al. Increased platelet CD63 andP-selectin expression persist in atherosclerotic ischemic stroke[J].Platelets, 2004,15(1):3-7.
[27]．陈字杰，陆信武，蒋米尔．P-选择素与动脉粥样硬化形成[J]．国外医学·生理、病理科学与临床分册，2002，22(4)：323-325．
[28]．许丹焰．P选择素在心血管疾病中的研究进展[J]．国外医学生理病理分册，1997，17：252-254．
[29]．倪俊．选择素拮抗治疗[J]．国外医学生理病理分册，1998，18：306-308．
[30]. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated Creactive protein levels and impared endothelial vasoreaetivity in patients with coronary artery disease. Circulation, 2000, 102:1000—1006.
[31]. Ridker PM. Stampfer MJ. Rifai N, Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease[J]. JAMA, 2001, 285(19): 2481-2485.
[32]. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000, 342(12): 836-844.
[33]．陈凤英，高炜，唐朝枢．CD40—CD40配体与动脉粥样硬化的研究进展[J]．中国动脉硬化杂志，2006年，14(8)：731-733．
[34]．谢扬，饶邦复．动脉粥样硬化血栓形成[J]．世界今日医学杂志，2005；6(4)：236-240．
[35]. Herman MP, Sukhova GK, Libby P, et al. Expression of neutmphil- collagenase(matrix metalloproteinase-8) in. human atheroma: a novelcollagenolytic pathway suggested by transcriptional profiling[J]. Circulation, 2001, 104(16).: 1899-1904.
[36]. Libby P, Geng YJ, Aikawa M, et al. Macrophages and athemsclerotic plaque stability[J]. Curt Opin Lipidol, 1996, 7(5): 330-335.
[37]. Badimon JJ, Lettino M, roschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombo—genicity under flow conditions[J]. Circulation, 1999, 99(14): 1780—1787.
[38]. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atheroselerotic plaques[J]. Circulation, 1997, 95(3): 594-599.
[39]. Moons AH, Levi M, Peters IL1. Tissue factor and coronary artery disease[J]. Cardiovasc Res, 2002, 53(2): 313-325.
[40]. Tedgui A. Mallat Z. Apoptosis as a determinant of atherothrombosis[J], Thromb Haemost, 2001, 86(1): 420-426.
[41]. Chamorro A. Role of inflammation in stroke and atherothrombosis[J]. Cerebrovasc Dis, 2004, 17(Suppl 3): 1-5.
[42]．周卫东．氧化型低密度脂蛋白的血管运动效应[J]．国外医学生理病理科学与临床分册，2000，20(1)：52-54．
[43]．赵洪东，周天虹．动脉粥样硬化与细胞凋亡[J]．武警医学院学报，2001，10(2)：171-173．
[44]. Hutter R, Valdiviezo C, Bernhard V, et al. Caspase—3 and Tissue Factor Expression in Lipid—Rich Plaque Macro phages. Evidence for Apoptosis as Link Between Inflammation and Atherothrombosis[J].Circulation, 2004, 109(16): 2001-2008.
[45]. Mallat Z. Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease[J]. Circ.Res, 2001, 88(10): 998-1003.
[46]. Mallat Z, Benamer H, Hugel B, et al.. Elevated levels of shed membrane micropartieles with pracoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes[J], circulation, 2000, 101(8): 841—843.
[47]．黄成磊，罗心平．阻断细胞凋亡药物在冠心病治疗中的研究[J]．国际心血管病杂志，2006，33(6)：377-380．
[48]．刘彤，沈潞华．雌激素抑制去卵巢家兔实验性主动脉硬化的形成[J]．中国动脉硬化杂志，1998，6(4)：121—123．
[49]．吴练秋，赵庆伟．糖皮质激素与动脉粥样硬化的关系[J]．中国动脉硬化杂志，1999，7(4)：360-362．
[50]．陈浩，严晓伟．过氧化物增殖激活受体在动脉粥样硬化形成过程中的作用[J]．世界医学杂志，2004，8(1)：70-72．
[51]．胡琴，张运．过氧化体增殖物激活型受体各亚型与动脉粥样硬化形成[J]．中国动脉硬化杂志，2005，13(5)：662-666．
[52]. Raueh U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical eonsequencesv[J]. Ann Intern Med, 2001, 134(3): 224—23.